MedPath

KRKA, d.d., Novo mesto

🇸🇮Slovenia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

18

Active:18
Completed:0

Trial Phases

1 Phases

Phase 1:15

Drug Approvals

57

EMA:34
PHILIPPINES:22
NPRA:1

Drug Approvals

Pomalidomide Krka

Authorization Status
Authorised
Approval Date
Jul 24, 2024
EMA

Pomalidomide Krka

Authorization Status
Authorised
Approval Date
Jul 24, 2024
EMA

Abiraterone Krka

Authorization Status
Authorised
Approval Date
Jun 24, 2021
EMA

Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka)

Authorization Status
Authorised
Approval Date
Feb 11, 2021
EMA

Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto)

Authorization Status
Authorised
Approval Date
Feb 11, 2021
EMA

Febuxostat Krka

Authorization Status
Authorised
Approval Date
Mar 28, 2019
EMA

Atazanavir Krka

Authorization Status
Authorised
Approval Date
Mar 25, 2019
EMA

Atazanavir Krka

Authorization Status
Authorised
Approval Date
Mar 25, 2019
EMA

Pemetrexed Krka

Authorization Status
Withdrawn
Approval Date
May 22, 2018
EMA

Efavirenz/Emtricitabine/Tenofovir disoproxil Krka

Authorization Status
Authorised
Approval Date
Feb 8, 2018
EMA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

Clinical Trials

Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials

Phase 1
15 (100.0%)
No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.